Asset Publisher

ph-1195

print Print Back Back

Antitussive Combination Products Quantity Limit Program Summary

Policy Number: PH-1195

This program applies to Blue Partner, Commercial, GenPlus, NetResults A series, SourceRx and Health Insurance Marketplace formularies.

POLICY REVIEW CYCLE 

 

Effective Date

Date of Origin   

04-01-2024           

FDA APPROVED INDICATIONS AND DOSAGE

See package insert for FDA prescribing information:  https://dailymed.nlm.nih.gov/dailymed/index.cfm

POLICY AGENT SUMMARY QUANTITY LIMIT

Target Brand Agent Name(s)

Target Generic Agent Name(s)

Strength

QL Amount

Dose Form

Day Supply

Duration

Addtl QL Info

Allowed Exceptions

Targeted NDCs When Exclusions Exist

Hydrocod Polst-Chlorphen Polst Cap ER 12HR 10-8 MG

20

Capsules

30

DAYS

Not covered for patients less than 18 years of age.

Hydrocod Polst-Chlorphen Polst ER Susp 10-8 MG/5ML

10-8 MG/5ML

100

mLs

30

DAYS

Not covered for patients less than 18 years of age.

Tuxarin er

Codeine Phos-Chlorpheniramine Maleate Tab ER 12HR 54.3-8 MG

54.3-8 MG

20

Tablets

30

DAYS

Not covered for patients less than 18 years of age.

Tuzistra xr

Codeine Polist-Chlorphen Polist ER Susp 14.7-2.8 MG/5ML

14.7-2.8 MG/5ML

200

mLs

30

DAYS

Not covered for patients less than 18 years of age.

ADDITIONAL QUANTITY LIMIT INFORMATION

Wildcard

Target Brand Agent Name(s)

Target Generic Agent Name(s)

Strength

Additional QL Information

Targeted NDCs When Exclusions Exist

Effective Date

Term Date

43995202366930

Hydrocod Polst-Chlorphen Polst Cap ER 12HR 10-8 MG

Not covered for patients less than 18 years of age.

04-01-2024

4399520236G110

Hydrocod Polst-Chlorphen Polst ER Susp 10-8 MG/5ML

10-8 MG/5ML

Not covered for patients less than 18 years of age.

43995202327430

Tuxarin er

Codeine Phos-Chlorpheniramine Maleate Tab ER 12HR 54.3-8 MG

54.3-8 MG

Not covered for patients less than 18 years of age.

4399520231G120

Tuzistra xr

Codeine Polist-Chlorphen Polist ER Susp 14.7-2.8 MG/5ML

14.7-2.8 MG/5ML

Not covered for patients less than 18 years of age.

CLIENT SUMMARY – QUANTITY LIMITS

Target Brand Agent Name(s)

Target Generic Agent Name(s)

Strength

Client Formulary

Hydrocod Polst-Chlorphen Polst Cap ER 12HR 10-8 MG

Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx

Hydrocod Polst-Chlorphen Polst ER Susp 10-8 MG/5ML

10-8 MG/5ML

Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx

Tuxarin er

Codeine Phos-Chlorpheniramine Maleate Tab ER 12HR 54.3-8 MG

54.3-8 MG

Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx

Tuzistra xr

Codeine Polist-Chlorphen Polist ER Susp 14.7-2.8 MG/5ML

14.7-2.8 MG/5ML

Blue Partner ; Commercial ; GenPlus ; Health Insurance Marketplace ; NetResults A Series ; SourceRx

QUANTITY LIMIT CLINICAL CRITERIA FOR APPROVAL

Module

Clinical Criteria for Approval

Quantity Limit for the Target Agent(s) will be approved when BOTH of the following are met:

  1. The patient is 18 years of age or older AND
  2. ONE of the following:
    1. The requested quantity (dose) does NOT exceed the program quantity limit OR
    2. The requested quantity (dose) is greater than the program quantity limit AND ONE of the following:
      1. BOTH of the following:
        1. The requested agent does not have a maximum FDA labeled dose for the requested indication AND
        2. Information has been provided to support therapy with a higher dose for the requested indication OR
      2. BOTH of the following:
        1. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication AND
        2. Information has been provided to support why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit OR
      3. BOTH of the following:
        1. The requested quantity (dose) is greater than the maximum FDA labeled dose for the requested indication AND
        2. Information has been provided to support therapy with a higher dose for the requested indication

Length of Approval: up to 12 months

This pharmacy policy is not an authorization, certification, explanation of benefits or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All pharmacy policies are based on (i) information in FDA approved package inserts (and black box warning, alerts, or other information disseminated by the FDA as applicable); (ii) research of current medical and pharmacy literature; and/or (iii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.

The purpose of Blue Cross and Blue Shield of Alabama’s pharmacy policies are to provide a guide to coverage. Pharmacy policies are not intended to dictate to physicians how to practice medicine. Physicians should exercise their medical judgment in providing the care they feel is most appropriate for their patients.

Neither this policy, nor the successful adjudication of a pharmacy claim, is guarantee of payment.

ALBP _  Commercial _ CS _ Antitussive_Combination_Products_QL _ProgSum_ 04-01-2024  _© Copyright Prime Therapeutics LLC. February 2024 All Rights Reserved